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In May 2011, Portugal signed the Memorandum of Understanding in which it guarantees a reduction in the 
public spending on pharmaceuticals. The aim of this research work is to analyse the possibility of hospital cost 
reductions in HIV, oncology and rheumatism related pharmaceutical drugs, by better practice of medical 
physicians. The patterns of drug prescriptions were modelled using a relative distribution, stochastic dominance 
analysis and an ordered probit model. It was found that there is great divergence in expenditure levels of 
pharmaceutical products across hospitals and medical specialties. Outlier physicians tend to maintain their 
prescribing behaviour, even after the introduction of feedback. Therefore, there is room to reduce hospital costs 
of pharmaceutical products, by better practice.   
Keywords: Prescription Patterns; Pharmaceutical Products; Hospitals; Portugal 
1. Introduction 
The majority of the population gets in touch with the health care sector in several occasions: as patients, policy 
makers, providers, taxpayers and as citizens.
1
 In what concerns the European Union member-states, a 
Eurobarometer survey showed that healthcare is seen as the 5
th
 vital matter, being considered more essential 
than both housing and education.
2
According to the World Health Report of 2010, four out of ten causes that 
lead to inefficiencies in the health care sector are associated with pharmaceutical products: prices, quality, use 
and waste.  
In May 2011, the Economic Adjustment Program for Portugal was settled, followed by the signing of the 
Memorandum of Understanding and the Loan Agreement.
3
 In line with the Memorandum of Understanding 
on Specific Economic Policy (MoU), Portugal needs to ensure a reduction in the public spending on 
pharmaceuticals of about 1% of GDP in 2013.
4
 Furthermore, Portugal has to develop its monitoring system of 
medical drugs. This includes a tougher assessment of each individual physician’s prescriptions in what 
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concerns volume and total value, regarding the prescription guidelines that were set. Therefore, feedback must 
be given to medical physicians on a regular basis, especially information concerning the most used and the 
costliest medical drugs. From August 2012 on, physicians working in Centro Hospitalar Central de Lisboa, the 
provider of this database, are given feedback on their expenditure in pharmaceuticals and the expenditure 
incurred by their colleagues. The unit price of each pharmaceutical product prescribed is not included. This 
feedback appears is each physician’s intranet personal page, which requires a password. Physicians play an 
important role since they are the agents that decide which pharmaceutical product to prescribe, influencing the 
hospital’s total expenditure. Therefore, given the aforementioned circumstances, it is important to study and 
identify physicians’ prescription patterns. 
The importance of understanding medical physicians’ prescribing patterns relies on the fact that the 
pharmaceutical drugs expenditures can substantially change depending on the way doctors prescribe. 
According to the Law of Large Numbers, each physician should treat similar patients, on average, in terms of 
health status and related expenditure. Hence, it should be expected that prescription patterns of pharmaceuticals 
would be similar across hospitals and across physicians with the same medical specialty.  
Therefore, the aim of this research work is to analyse the possibility of hospital cost reductions in 




 This analysis considers 
pharmaceuticals administered in a hospital setting, only. Furthermore, it will focus on particular diseases: 
HIV/AIDS, oncology and rheumatism. The criteria used for the selection of medical conditions were its 
relative weight and growth tendency in hospital costs. Every year, Portugal incurs in very high expenditure 
levels related to HIV/AIDS treatment (an average cost of treatment of €13.625 per patient-year). Antiretroviral 




 In this database, which only includes 
                                                          
5 
A good practice, according to the WHO (1987),  is one which “requires that patient receive medication appropriate to their clinical 
needs, in doses that meet their own individual requirement for an adequate period of time and at the lowest cost to them and their 
community” 
6
 Hospital pharmaceutical drugs will be defined as all pharmaceutical drugs administered in a hospital setting, for both inpatients 
and outpatients 
7
 According to the WHO (2010) antiretroviral treatment “consists of the combination of at least three antiretroviral (ARV) drugs” 
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pharmaceutical products’ costs, the six hospitals together spent €60.238.005,52 during the six quarters of 
available data. The direct costs of cancer treatment in Portugal, represent 3,91% of the total expenditure in 
health care, which means €53 per capita. In what concerns the total expenditure on pharmaceutical drugs, 
oncology drugs are responsible for 5,6% of this amount.
9
 Ageing is an important determinant in what concerns 
rheumatism.
10




The patterns of drug prescriptions by physicians in six public hospitals in Lisbon were modelled using a 
relative distribution model and a stochastic dominance analysis. The relative distribution analysis represents a 
way to compare expenditure levels between physicians. Therefore it is possible to identify outlier physicians 
(physicians incurring into higher or lower expenditure levels than the norm, on average,  in comparison to their 
colleagues).
12
 The stochastic dominance analysis allows an intertemporal comparison of expenditure levels for 
each physician. A regression using a probit model was carried out to determine which variables are significant 
in explaining outlier physicians above and below the norm. My findings show that there is great divergence of 
prescribing patterns across physicians, the hospitals where they prescribe and their medical specialty. Outlier 
physicians, incurring into higher or lower expenditure levels than the norm, tended to maintain their prescribing 
patterns in the observation period. Even after the introduction of individual feedback their prescribing 
behaviour did not show major changes. Concerning the evolution of total pharmaceutical product costs, a 
decrease in product prices does not seem to have had a permanent impact in expenditure levels.  
The remainder of this paper is as follows. Section 2 presents a brief literature review related to physicians 
prescribing behaviour. This is followed by the description of data and the methodology in Section 3. The 
achieved project results are addressed in Section 4. Section 5 presents conclusions and main limitations. 
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According to Barnett and Lewis (1994) an outlier is: “An observation (or subset of observations) which appears to be inconsistent 
with the remainder of that set of data.” 
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2. Literature Review 
Pharmaceutical treatment choices can be influenced by both demand-side and supply-side factors.
13
 Demand-
side factors include prices, personal preferences and income. The database of this work only refers to 
pharmaceutical products that are given for free to every patient, in public hospitals, making the treatment choice 
independent of the patients’ decisions.  Supply-side factors include the technology available to perform the 
different treatment choices. Carone et al. (2012) identified several ways to influence and try to improve the way 
medical physicians prescribe as prescription monitoring, prescription guidelines, targets for prescription costs, 
prescription quotas, financial incentives and educational training.  
Hogerzeil (1995) classified strategies to promote a rational prescribing behaviour into three different categories: 
educational, managerial and regulatory. In what concerns their possible effectiveness, the author concludes that 
educational strategies, such as printed materials of drug lists and treatment guidelines, alone are unlikely to 
influence prescription patterns unless they are followed by introductory campaigns and these physicians take 
part on the process. Furthermore, he highlighted the importance of achieving consensus among physicians 
when introducing treatment protocols and drug lists. Moreover, Schroeder et al. (1984) found that given 
feedback individually for each physician may actually be so costly that will offset the potential gains. 
Allan et al. (2007) found that physicians lack knowledge in what concerns the costs of pharmaceutical drugs, 
often underestimating the price of expensive drugs. Nonetheless, Hart (1997) concluded, that family physicians 
tend to prescribe less expensive drugs even before having prior information about their costs.   
3. Data and Methodology 
3.1. Data 
The data source for this project comes from different hospitals located in Lisbon. They belong to Centro 
Hospitalar de Lisboa Central. The hospitals are: Hospital Curry e Cabral (HCC), Hospital de São José (HSJ), 
Hospital Santo António dos Capuchos (HSAC), Hospital de Santa Marta (HSM), Hospital Dona Estefânia 
(HDE) and the Maternity Hospital Alfredo da Costa (MAC). The data refers to the period from the 1
st
 quarter 
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of 2012 to the 2
nd
 quarter of 2013. Each Hospital has different main medical specialties, as well as capacity 
(number of beds) as it can be seen in the table below (information regarding the main specialties of HCC and 
MAC was not available): 
Table 1 – Hospitals’ capacity and main specialties description 
 
In 2012, HSJ, HSAC and HDE were already using a common database. Only in 2013, HCC, HSM and 
MAC started to be included in this database. Therefore, for any analysis of the current database, one needs to 
take into account that before 2013 HCC, HSM and MAC were registering episode numbers and patient 
numbers independently from the other hospitals already with a common database. Thus, different patients 
from different hospitals may, in 2012, have the same patient number. 
Furthermore, it may happen that the same patient has different hospital numbers. Likewise, it may occur that 
the same episode number in different hospitals in 2012 represented different and not related episodes. The latter 
problem was overcome by analysing not the episode number but a code aggregating both, the episode and the 
patient number, so repetitions are avoided. In what concerns patients, a code aggregating both the patient 
number and the hospital name was created. In 2013 this problem does not arise since the database already 
includes all hospitals in a consistent coding procedure. A given episode contains information regarding 
patient’s health problem currently being treated and the description of the provided service according to 
different medical specialties as well as the drugs that were provided and their cost. There is also information 
concerning which one was the physician responsible for each episode. This record focuses on the 
characteristics of the drugs prescribed to the patients in the hospital. It includes the beginning and the end date of 
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the treatment of the given pharmaceutical, the dose and the frequency, the quantity, the unit cost and the total 
cost of the prescribed pharmaceutical.
14
    
The information gathered allows not only an intra-hospital comparison, but also the possibility to monitor 
pharmaceutical costs between institutions. 
3.2. Methodology 
3.2.1. Relative Distribution 
To compare expenditure levels between physicians, a relative distribution analysis is used. Therefore it is 
possible to identify outlier physicians, physicians incurring into higher or lower expenditure levels than the 
norm, in comparison to their colleagues.
15
 Hence, this method detects physicians which incurred into 
significant deviations from a given (average) prescription pattern. 
Relative distributional methods consist of non-parametric statistical processes. Nonparametric density estimates 
allow for the comparison between groups and to a group with a benchmark density (e.g. the normal).
16
 It does 
not require the adoption of assumptions in what concerns the mathematical form of the probabilities 
distribution of a variable.
17
 Hence, non-parametric models prevent violations of the hypothesis of models 
which would lead to misleading answers. The two histograms below, showing the expenditure level of two 
specific medical physicians, highlight how hard it would be to find a benchmark density suitable for every 
medical physician regarding his/her number of prescriptions over prices/value per prescription:  
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Moreover, it contains a graphical component, which simplifies the analysis.  
This method establishes an association among distributions, allowing the possibility of making direct 
comparisons between groups or points in time, with respect to a continuous outcome variable.  A reference 
group must be set, as well as a comparison group. Comparisons are done by getting comparison group’s points 
and understand where they fall in the reference distribution (i.e. in which quantile). Thus, it converts two 
distributions into a single one allowing for an analysis that is scale independent (it shows the set of percentage 
positions that the observations of one distribution would have were they located in another distribution). If both 
distributions are equal, then the “relative data” will be uniformly distributed.  
As stated by Handcock e Morris (1999), relative distribution methods include particularities such as not being 
affected by the scale choice or to monotonic transformations, basing its study in the population and not the 
individual and it computes proportions of individuals and calculates their ranking position. 
Let Y0 be the outcome variable in the reference group, and Y be the outcome variable in the comparison group. 
It is usually the measurement for a different group or it can be the identical group in another time period.  
Being F0 the distribution function of the reference group we have that  
R= F0 (Y) 
The Cumulative Distribution Function (CDF) of the relative data R is given by: 
G(r) = F [F0
-1
 (r)] = Q0 (r) 0≤r≤1 where Q0 (r) is the quantile function of the reference distribution 
Taking the first order derivative of G(r) the density function is obtained: 
g(r) = f{[F0
-1
 (r)]} / f0{[F0
-1
 (r)]} = f [Q0 (r)]/ f0[Q0 (r)]                0≤r≤1 where f and f0  are density functions 
The relative distribution allows to directly compare one distribution with another. 
It is expressed as a random variable which was attained by converting a variable from the comparison group 
by the CDF of that variable for a reference group. This conversion will lead to a set of observations (relative 
data), which characterise the rank of the initial comparison value in terms of the CDF of the reference group. 
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The Probability Density Function (PDF) may be interpreted as a density ratio between two different 
distributions i.e., “the ratio of the fraction of respondents in the comparison group to the fraction in the reference 
group at a given level of the outcome attribute”.  To use the relative distribution model one only needs to 
include those that have prescribed at least more than four times.  
To complement the visual component, the Kolmogorov-Smirnov test is used to test the hypothesis whether 
two samples follow the same distribution or not.
18
 Specifically, it will be compared the distribution of the 
expenditure level of each physician with the expenditure level of the other physicians excluding himself/herself. 
The null hypothesis assumes that the samples are drawn from the same distribution. This test requires 
continuous distributions, as in this case, and it is a non-parametric method. Therefore, such analytical 
components are appropriate to use in this analysis.  
3.2.1 Stochastic Dominance   
To compare the evolution of each physician’s expenditure across time the stochastic dominance analysis is 
applied. Stochastic dominance approaches have been traditionally applied in economics in relation to assets 
with monetary payoffs and in relation to poverty and income distribution analysis.
19
  
The several types of pharmaceutical drugs used in each type of medical treatment entail an expenditure 
distribution. In this case, the First Stochastic Dominance (FSD) will be useful to compare expenditure levels, 
between two periods, for each doctor.  Therefore, applying a stochastic dominance technique offers the 
opportunity to identify whether expenditure levels for a given physician have been rising or falling across time. 
However, one has to consider that a physician’s expenditure level in pharmaceuticals is also affected by price 
effects. A specific case is a modification in law that may contribute to changes in pharmaceutical expenditures 
across time. Indeed, since the 1
st 
of March of 2013, the reference prices for pharmaceutical products changed.
20
 
The assumption is that both, the physicians’ and patients’ characteristics, remain constant across time.  
3.2.1.1 First-degree stochastic dominance (FSD)  
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Suppose that there are two possible distributions F and G, with cumulative density functions (CDF) of 
F(x)=Pr(X≤x) and G(x)=Pr(X≤x).  
The CDF of F(x) dominates G(x) by first degree stochastic dominance if and only if:  
F(x)≤G(x), for all x 
3.2.3. Ordered probit model  
An ordered probit model is implemented to assess which characteristics associated with the outlier physicians 
are significant in explaining their expenditure levels’ deviation to the norm. This model was not run for 
rheumatism since there are too few observations. The dependent variable, being an outlier (y) is a limited 
dependent variable which takes the following form: y=1 if the physician is an outlier with an expenditure level 
above the norm and y=-1 if the physician is an outlier with an expenditure level below the norm and y=0 his 
expenditure is according to the norm. 
                           -1 if the physician is an outlier with an expenditure level below the norm 
Y =              0 his expenditure is according to the norm   
                           1 if the physician is an outlier with an expenditure level above the norm 
Being yi* = xi’β + ui a latent index model where yi = (-1,0,1) For a three alternative ordered probit model: 
yi =-1 if yi* ≤ α1 
yi=0 if  α1< yi*≤ α2 
yi=1 if yi*≥  α2 
Thresholds separate the ordering of alternatives. In this case we have: 
Pr(yi =-1) = Pr(yi ≤ α1) = Pr(xi β +εi ≤ α1) = Pr(εi ≤ α1- xi β) = Φ[α1- xi β] = 1- Φ[xi β – α1]  
Pr(yi=0) = Pr(α1 < yi* ≤ α2) = Pr(yi* ≤ α2) – Pr(yi* ≤ α1)= Pr(xi β +εi ≤ α2) – Pr(xi β +εi ≤ α1) = Pr(εi ≤ α2- xi β) - 
Pr(εi ≤ α1 - xi β) = Φ[α2- xi β] - Φ[α1- xi β] =  1 - Φ[xi β – α2] – 1 + Φ[xi β - α1]  = Φ[xi β - α1] - Φ[xi β – α2]                                                                                                                                         
Pr(yi=1) = Pr(yi* > α2) = Pr(xi β +εi > α2) = Pr(εi > α2- xi β) = 1 - Φ[α2- xi β] = Φ[xi β – α2] 




It would be desirable to include other characteristics of the physicians such as sex, age and education level. 
Unfortunately such information was not available. Unordered multinomial models could also be used, but to 
take into account the ordering makes this model more parsimonious. P is the probability of the outcome. 
To ensure that 0 ≤ p ≤ 1 it is natural to specify F(·) to be a cumulative distribution function.21 In the case of the 
probit, this cumulative distribution function will be the standard normal one. The explanatory variables are the 
current hospital where the physician works, the number of prescriptions prescribed by him/her and his/her 
medical specialty. The aim is to understand which factors influence physicians’ prescribing patterns. Given the 
small number of observations in what concerns rheumatism, the model will only focus on HIV and oncology 
pharmaceutical products’ prescriptions. Since the ordered probit is constructed based on the results attained by 
the relative distribution, all physicians prescribing less than four times were excluded.  
4. Results 
4.1. HIV 
4.1.1. Comparisons among physicians  
This database includes 176 physicians prescribing HIV-related pharmaceutical products. However, only those 
prescribing more than four times were included in this analysis. Each physician’s expenditure was compared 
with his colleagues’ expenditure. Afterwards each graph was analysed as to conclude about the physician’s 
expenditure: physicians incurring into higher or lower expenditure levels than the norm, in comparison to their 
colleagues. HSJ, HSAC and HCC are the hospitals whose specialty is HIV cases and therefore, register a 
higher number of cases and a higher overall expenditure. Analysing a specific physician as an example: 
Graphic 3 and Graphic 4 
  
 
Probability density function                                                                         Cumulative density function 
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By looking at the probability density function, one sees that this physician shows a big discrepancy compared 
to his colleagues from around the 38
th
 to the 70
th
 percentile, showing a higher expenditure, on average, than his 
colleagues. However, from the 0
th
 to the 37
th
 and from the 70
th
 percentile on, it shows, on average, a lower 
expenditure than his colleagues. This means that this physician in particular prescribes a higher quantity of less 
expensive pharmaceutical drugs than his colleagues, but also a higher quantity of more expensive 
pharmaceutical products.  
By looking at all the computed graphs, it was notorious that there are many different patterns of prescription 
thus, it is not possible to establish a typology. Following the visual analysis of the graphs obtained in the relative 
distribution and the Kolmogorov-Smirnov test, physicians were separated in three different groups. Let -1 
represent physicians incurring into lower expenditure levels than the norm, in comparison to their colleagues, 0 
represent those prescribing values according to the norm, and 1 represent those incurring into higher 
expenditure levels. 
Table 2 – Relative distribution results after the Kolmogorov-Smirnov test 
 
Considering this, histograms were computed, taking into account that data is discrete and that the each class 
width is one, and therefore the density equals the relative frequency (since the density is the quotient of the 
relative distribution with the class width). Seeing the overall period of analysis (six quarters), the histogram 
below shows the density of the physicians’ expenditure levels.  One can conclude that the class with the highest 
density was the one that includes physicians incurring into expenditures according to the norm (0,5), followed 
by those incurring into lower expenditure levels than the norm (approximately 0,3) and lastly, by the ones 









Analysing semester by semester, one can see that the densities among each class in the first semester of 2012 
and in the first semester of 2013 look a-like, although in the latter one there is a higher density of physicians 
with an above the norm expenditure level. 
Graphic 6, Graphic 7 and Graphic 8 
 
2012 1st and 2nd Quarters; 2012 3rd and 4th Quarters; 2013 1st and 2nd Quarters  
To analyse prescription patterns per hospital where each physician was prescribing, in the overall period, 
histograms were computed. However, one should note that in each quarter, the average, which is the reference 
point, changes. In MAC and the density of physicians that are outliers prescribing below the average’s norm, in 
comparison to their colleagues is the greatest. Those prescribing in both HSAC and HSJ, have the same 
quantity of physicians prescribing on the norm and above it. One should also highlight that those prescribing in 
HSJ, HCC and HSAC; HSJ, HDE and in HSJ, HSM were never outliers, when considering the overall 
period).
22
 It should be highlighted that in the specific case of HSJ, physicians dealing with HIV cases gather 
and make prescribing decisions together.
23
 Across the three semesters, this hospital shows great density of 
physicians incurring into expenditure levels below the norm, in comparison to their colleagues (0,6; 0,4 and 0,6 
respectively). Thus, there is a great variation in prescribing patterns across hospitals.  
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Graphic 9, Graphic 10, Graphic 11, Graphic 12, Graphic 13and Graphic 14 
  
Alfredo da Costa; Santa Marta; Capuchos, S. José, while the last histograma refers to both São José, Curry e Cabral, Capuchos; São José, Estefânia and São José, Santa Marta 
Histograms across medical specialties were also computed.  
 
Dermatovenereology; Endocrinology; Anesthesiology, Internal Physician, Clinical Pathology and Urology 
In what concerns the medical specialty of the physicians prescribing HIV related pharmaceutical products,  the 
assumption is that the “type” of patients is not related to the specialty of the physician. Considering the 
“extreme” cases
24
, specialists in Dermatovenereology were only outliers below the norm, Endocrinology 
always above and Anesthesiology, Internal Physician, Clinical Pathology and Urology were always 
prescribing according to the norm.
25
 
4.1.2. Outlier physicians across semesters 
It is important to assess whether physicians are always showing the same outlier prescribing patterns in the 
period of analysis or if there is any change. For this purpose, the histograms below were computed for 
physicians with according to the norm, above the norm and below the norm expenditure levels. 
Graphic 15 and Graphic 16 
 
In what concerns physicians identified as outliers because they incurred into higher expenditure levels, half of 
them were outliers only during one period. The other half was showing this behaviour throughout three 
                                                          
24
 Hospitals which only registered outliers that incur into expenditure levels above or below the norm 
25 More details are available in the extra annexes, in the C.1.3. section 
15 
 
semesters (27%) and two semesters (23%). Thus, approximately half of the physicians considered outliers 
incurring into higher expenditure levels than the norm tend to maintain their prescribing patterns across the 
period of observation. 
Regarding physicians considered outliers with lower expenditure levels than the norm, the majority was 
showing this behaviour during two semesters, followed by those displaying this behaviour one semester.  
4.1.3. Expenditure levels across semesters 
A stochastic dominance approach was used to compare each physician’s expenditure level between two 
different periods. Consecutive quarters were analysed and compared, throughout a graphical analysis. The 
graph below illustrates this approach: 
Graphic 17 
 
Stochastic Dominance Function 
This figure represents a particular medical physician and his/her expenditure levels in the 1
st
 quarter of 2012 and 
on the 2
nd
 quarter of 2012. One can see that the distribution of the 2
nd
 quarter of 2012 is everywhere above the 
distribution of the 1
st
 quarter of 2012. Therefore, the distribution of the 1
st
 quarter of 2012 first order 
stochastically dominates the one of the 2
nd
 quarter of 2012. Assuming that the benefits are the same, lower 
expenditure levels are considered better. Therefore, in this specific case, expenditure with pharmaceutical 
products increased from one quarter to the other and the distribution developed in a undesired way.  
Being Dit = 1 if t stochastically dominates t-1 (the expenditure level in t is lower than in t-1) and Dit = 0 if t-1 
stochastically dominates t (the expenditure level in t-1 is lower than in t). 
16 
 
Graphic 18, Graphic 19, Graphic 20, Graphic 21 and Graphic 22 
 
 
For the majority of the physicians prescribing HIV related pharmaceutical products in the first semester of 
2012, the distribution of the 1
st
 quarter of 2012 first order stochastically dominates the one of the 2
nd
 quarter of 
2012. The expenditure level of HIV related pharmaceutical products has, therefore, increased from the 1
st
  to 
the 2
nd
  quarter of 2012 for more than a half of medical physicians. From the 2
nd
 to the 3
rd
 quarter of 2012, 
approximately more than a half of medical physicians increased their expenditure levels in pharmaceuticals. 
The same pattern occurs from the 3
rd
 to the 4
th
 quarter of 2012 and well as for the 1
st
 to the second quarter of 
2013. The period from the 4
th
 quarter of 2012 to the 1
st
 quarter of 2013 was an exception, in the sense that there 
were more physicians incurring into lower expenditure levels in the latter period (the 1
st
 quarter of 2013). Such 
event may be related to the fact that since August (3
rd
 quarter of 2012) physicians started to receive feedback 
about their and the total expenditure level in pharmaceuticals. It may also have to do with the fact that, since the 
1
st
 of March of 2013, the reference prices for pharmaceutical products changed.
26
 The newly selected countries 
were chosen based on their lower pharmaceutical products’ price.
27 The 1st semester of 2013 is the one that 
shows a higher discrepancy between the two quarters, with the majority of physicians incurring into higher 
expenditure levels in the 2
nd
 quarter. Thus, one can conclude that expenditure levels have been increasing over 
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time for most physicians, except in one period.  However, it is not possible to assess if this change was due to 
the number of treated patients since only after 2013 all the hospitals were using the same database. Thus, 
different patients from different hospitals may, in 2012, have the same patient number. Nevertheless, one can 
look at the quantity and unit price of the pharmaceuticals prescribed. In what concerns the unit price, there is an 
increase in the prescription of very costly pharmaceutical products since the first two quarters of 2012 (although 




Graphic 23 and Graphic 24 
 
2012 1st-2nd Quarter                                                 2012 2nd-3rd Quarter 
 
4.1.4. Significant Characteristics  
The explanatory variables include the number of prescriptions made by each physician, the medical specialty 
(a dummy variable with 1 being Infectiology and General Medicine and 0 the other specialties, since these are 
the two specialties which physicians register a larger number of episodes) and the hospital where he/she 
prescribes (dummy variables, being the omitted variable HSM). As it was previously stated in the data 
description, it is not possible to follow a patient by his/her hospital number. Neither patients’ nor physicians’ 
characteristics (e.g. age, education and job) are available. It might be possible that some of these variables could 
be significant into explaining different expenditure levels.    
Table 3 – Ordered probit results 
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Prescribing in HSAC is significant in the overall period of analysis and in two semesters, associated with 
positive coefficients. The medical specialty of the physician prescribing is significant in the 1
st
 semester of 2012.  
In the unordered probit case, the sign of each coefficient gives the direction of the effect, but not its marginal 
effect.
29
 The marginal effects of changes in the explanatory variables are given by:  
         
   




Table 4 – Probability of being an outlier with a below the norm expenditure level - P         
 
Table 5 - Probability having an expenditure level according to the norm -         
 
Table 6 – Probability of being an outlier with an above the norm expenditure level - P        
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The main result is that physicians prescribing in HSAC are more likely to be outliers incurring into 
expenditures above the norm (20 percentage points in the overall period and 28 percentage points in the 2
nd
 
semester of 2012) and less likely to be outliers incurring into expenditures below the norm (25 percentage 
points in the overall period and 34 percentage points in the 2
nd
 semester of 2012), in comparison to those 
prescribing in HSM (the omitted variable).  
4.2. Oncology  
4.2.1. Comparisons among physicians  
This dataset contains 193 physicians prescribing oncology related pharmaceutical drugs. However, to use the 
relative distribution model one needs to only include those that have prescribed at least more than four times, 
therefore only 135 physicians were analysed. 
The density of outliers incurring into higher expenditure levels than the average seems to be more or less 
constant across the three semesters.   
HSJ shows a decrease in outlier physicians prescribing levels above the norm throughout the three semesters. 
HSAC consistently has a great density of outlier physicians prescribing below the norm expenditure level. On 




There is also great divergence between medical specialties.
32
 Considering the overall period, there are six 
specialties which physicians are all outliers prescribing above the norm level and one where they are not 
outliers. However, in what concerns cancer, different medical specialties are related to several types of cancer.
33
 
Different types of cancer require different a treatment so, costs are not comparable across the different 
pathologies.  
4.2.2. Outlier physicians across semesters 
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In what concerns physicians identified as outliers because they have incurred into higher expenditure levels, on 
average, than their colleagues, most of them were showing this behaviour throughout the three semesters. By 
analysing the physicians that were identified as outliers that incurred into lower expenditure levels, than their 
colleagues, the majority also showed this pattern during the three semesters. Thus, most physicians have been 
maintaining their prescribing patterns unchanged.
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4.2.3. Expenditure levels across semesters 
The expenditure level of oncology related pharmaceutical products has increased from the 1
st
 to the 2
nd
 quarter 
of 2012, from the second to the third quarter of 2012 and from the 4
th
 quarter of 2012 to the 1
st
 quarter of 2013 . 
On the other hand, from the 3
rd
 to the 4
th
 quarter of 2012 and from the 1
st
 to the 2
nd
 quarter of 2013 there is a 
greater density for physicians incurring into lower expenditure levels in the latter period.  This might be related 
to the fact that since August (in the 3
rd
 quarter of 2012) physicians started to have feedback about their and the 
total expenditure level in pharmaceuticals Furthermore, since the 1
st
 of March of 2013, the reference prices for 
pharmaceutical products changed. The newly selected countries were chosen based on their lower 
pharmaceutical products’ price. With respect to the quantity and the unit price of the pharmaceutical products 
prescribed, there are no major changes across these 1,5years. In some periods, there is a small density of 
pharmaceutical products which unit price is extremely high (more than 1000€), which may be related to very 
acute episodes.  
4.2.4. Significant Characteristics  
In what concerns cancer, different medical specialties are related to several types of cancer, as it was stated 
before. Across each semester and in the overall period the only significant variables are those concerning the 
physician’s medical specialty. However, one cannot do such comparison. In what concerns the number of 
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4.3.1. Comparisons among physicians  
In what concerns physicians prescribing for rheumatology, they are concentrated in three out of the six 
hospitals: HCC, HSAC, and HDE. HCC seems to have more physicians incurring into higher expenditure 
levels than the norm. This pattern is consistent throughout the different semesters. The opposite happens with 




General Medicine is the medical specialty with more physicians with expenditure levels above the norm, 
when considering the overall period. In what concerns the specialty of the medical physicians below the norm 
, the results show that the majority are specialists in Anesthesiology and Pediatrics. This is true both for the 
overall period and for each semester.
37
  
4.3.2. Outlier physicians across semesters 
Regarding physicians identified as outliers because they incurred into higher expenditure levels, on average, 
than their colleagues, the majority were showing this behaviour throughout two semesters followed by those 
showing this behaviour during three semesters. There was no physician showing this pattern only in one 
semester. 
By analysing the physicians that were identified as outliers that incurred into lower expenditure levels than their 
colleagues, the majority showed this pattern during one semester, followed by those showing this behaviour 
during three semesters. 
4.3.3. Expenditure levels across semesters 
                                                          
35
 More details are available in the extra annexes, in the C.2.5. section 
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Expenditure levels in pharmaceuticals have been decreasing in 3 out of 5 periods (from the first to the 2
nd
 
quarter of 2012, from the 2
nd
 to the 3
rd
 quarter of 2012 and from the 4
th
 quarter of 2012 to the 1
st
 quarter of 
2013). Thus, expenditure levels have been decreasing over time for most physicians, except for two periods. 
Regarding the unit price, there is an increase in the prescription of very costly pharmaceutical products since the 




Regarding HIV, there is a great variation in prescribing patterns across hospitals. One should highlight the case 
of HSJ, where physicians dealing with HIV cases gather and make prescribing decisions together. During the 
observation period, this hospital shows a high density of physicians incurring into expenditure levels below the 
norm, in comparison to their colleagues. Concerning the permanence/change of the prescribing behaviour by 
physicians, it was found that approximately half of the physicians that were considered as outliers, incurring 
into higher expenditure levels than the norm tend to maintain their prescribing patterns across these 1,5 years. 
Expenditure levels in pharmaceutical products have been increasing over time for most physicians, except in 
one period. With respect to the unit price, there is an increase in the prescription of very costly pharmaceutical 
products since the first two quarters of 2012, however the quantity prescribed did not register major changes 
across time. The unordered probit model consistently shows that physicians prescribing in HSAC have a 
higher probability of being outliers incurring into higher expenditures than the norm and a lower probability of 
being outliers incurring into lower expenditure levels than the norm, in comparison to those prescribing in 
HSM (the omitted variable).   
Physicians prescribing oncology-related pharmaceutical products seem to have very different prescription 
patterns according to the hospital where they prescribe. HSJ shows a decrease in outlier physicians prescribing 
levels above the norm throughout the three semesters. HSAC consistently has a great density of outlier 
physicians prescribing below the norm expenditure level. HCC displays a great density of outlier physicians 
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prescribing levels above the norm throughout the three semesters. Regardless of the hospital, most physicians 
have been maintaining their prescribing patterns unchanged. There are also great differences across medical 
specialties. However, different types of cancer require different treatments and thus,, costs are not comparable 
across different pathologies. As to the stability of outlier behaviour, most physicians have not been changing 
their prescribing patterns. With respect to the quantity and the unit price of the pharmaceutical products 
prescribed, there are no major changes across the observation period. In some periods, pharmaceutical products 
with a extremely high unit price (more than €1.000, while almost all the others cost less than €500) are 
prescribed. However, they only represent a small density of the overall products. This may be related to very 
acute episodes, which require costlier products.  
In what concerns rheumatism, physicians are concentrated in three out of the six hospitals: HCC, HSAC, and 
HDE. HCC seems to have more physicians incurring into higher expenditure levels than the norm. This 
pattern is consistent throughout the different semesters. The opposite happens with HSAC and HDE, which 
have a higher proportion of physicians incurring into lower expenditure levels than the norm. Most of outlier 
physicians that incur in higher expenditures maintain their prescribing behaviour throughout this period. In 
contrast, those that incur in lower expenditure levels than the norm do not maintain their prescribing behaviour. 
Expenditure levels have been decreasing over time for most physicians, except for two periods. Regarding the 
unit price, there is an increase in the prescription of very costly pharmaceutical products since the first two 
quarters of 2012. In what concerns the quantity, it seems that there are no major changes across time.  
Overall, there is great divergence of prescribing patterns across physicians, the hospitals where they prescribe 
and their medical specialties.  Physicians tended to maintain their prescribing patterns across these 1,5 years, 
whether they were outliers incurring into higher or lower expenditure levels than the norm and even after the 
introduction of the individual feedback. With respect to the evolution of total costs of pharmaceutical products, 
the price decrease of pharmaceuticals does not seem to have had a permanent impact in expenditure levels.  
24 
 
The results stated above show a discrepancy in relation to the Law of Large Numbers. This law states that, on 
average, each physician should treat similar patients, in terms of health status and related expenditure. Hence, it 
should be expected that prescription patterns of pharmaceuticals would be similar across hospitals and across 
physicians with the same medical specialty. Therefore, there is room to reduce hospital costs of pharmaceutical 
products, by better practice of physicians. 
Nevertheless, it would be valuable to have information regarding the treated patients. Then one could assess 
whether physicians that are always incurring into expenditure levels above the norm were treating patients that 
could justify the use of costlier pharmaceutical products or not (since in some cases the application of the Law 
of Large Numbers might be unsuitable). If it would be found that such patients did not require costlier 
pharmaceutical products, then one could conclude that these physicians should change their prescribing 
behaviour while the other ones (incurring into below the norm expenditure levels) should be emphasised as 
having a better practice.  
Future research should include a method, such as the differences-in-differences one, to evaluate whether 
physicians change their prescription patterns when they are provided with better information regarding their 
prescription behaviour. Furthermore, in the specific case of HIV, it would be interesting to assess the impact of 
physicians prescribing pharmaceutical products together, by analysing the case of HSJ. 
39
 Moreover, having 
information about the patients’ as well as physicians’ characteristics (e.g. sex, age and education level.) could be 
beneficial for further research.  
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A.1. Database Description 





B – Detailed Methodology 
B.1. Kolmogorov-Smirnov Test 
The two-sample Kolmogorov-Smirnov test (Dn) is used to assess whether or not two 
samples follow the same distribution, by comparing each cumulative distribution 
function.   
Taking F(x) and G(x) as empirical distribution functions for the sample being 
compared, the hypotheses being tested are: 
D
+
=maxx {F(x) – G(x)}  
D
-
= minx {F(x) – G(x)} 







As an example: 
Smaller group       D            P-value  Corrected 
----------------------------------------------------------- 
0:                            0.1168    0.682 
1:                           -0.5206    0.001 
Combined K-S:     0.5206     0.001      0.000 
 
The first line tests the hypothesis that the Expenditure for group 0 (every physician 
excluding the one being analysed) contains smaller values than for group 1 (the 
physician being analysed). Since the p-value is 0,682, it is not significant and thus we 
cannot reject the null hypothesis.  
The second line tests the hypothesis that the Expenditure for group 0 contains larger 
values than for group 1. The p-value is 0,001, which is significant. Thus, the null 
hypothesis is rejected.  
 
B.2. Ordered Probit Model 
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When the dependent variable has a finite number of possible outcomes, the data is 
called multinomial. In this case, the dependent variable chosen assumes three different 
values. The dependent variable not only assumes three different values, but is also 
ordinal in the sense that it assumes that there is a latent continuous metric underlying 
the ordinal responses observed by the analyst. 
-1 if the physician is an outlier with an expenditure level below the average 
Y =               0 his expenditure is according to the norm 
1 if the physician is an outlier with an expenditure level above the average 
Therefore binary response models are not suitable for this analysis, since in these 
models the dependent variable can only assume two different values.  
In what concerns the choice between an ordered probit or an ordered logit, Heij et al.  
(2004) state that “there are often no compelling reasons to choose between the logit and 
probit model”. 
Being yi* = xi’β + ui a latent index model where yi = (-1,0,1) For a three alternative 
ordered probit model: 
yi =-1 if yi* ≤ α1 
yi=0 if  α1< yi*≤ α2 
yi=1 if yi*≥  α2 
Thresholds separate the ordering of alternatives. In this case we have: 
Pr(yi =-1) = Pr(yi ≤ α1) = Pr(xi β +εi ≤ α1) = Pr(εi ≤ α1- xi β) = Φ[α1- xi β] = 1- Φ[xi β – α1]  
Pr(yi=0) = Pr(α1 < yi* ≤ α2) = Pr(yi* ≤ α2) – Pr(yi* ≤ α1)= Pr(xi β +εi ≤ α2) – Pr(xi β +εi ≤ α1) = 
Pr(εi ≤ α2- xi β) - Pr(εi ≤ α1 - xi β) = Φ[α2- xi β] - Φ[α1- xi β] =  1 - Φ[xi β – α2] – 1 + Φ[xi β - α1]  = 
Φ[xi β - α1] - Φ[xi β – α2]                                                                                                                                         
Pr(yi=1) = Pr(yi* > α2) = Pr(xi β +εi > α2) = Pr(εi > α2- xi β) = 1 - Φ[α2- xi β] = Φ[xi β – α2] 




The sign of the regression parameters β gives the direction of the effect i.e., whether or 
not the latent variable y* increases or decreases with a change in the regressor. 
However, it gives no information regarding the sign of the marginal effect.   
The marginal effects of changes in the explanatory variables are given by:  
 
         
   
 {F(αj-1-xiβ) - F(αj-xiβ)}β  
 
Marginal effects can be used with categorical variables, which are included in this 
ordered probit.  
B.3.Differences-in-Differences  
To assess whether or not making physicians aware of their expenditure levels in 
pharmaceutical products a Differences-in-Differences (DD) method could be used.  
The DD method provides a tool to estimate causal effects when using panel data that 
contains groups of observations which are exposed and not exposed to a causing 
variable.  
The treatment, an exogenous event, would only affect a set of individuals, the treated 
individuals. Physicians in these six hospitals are given feedback about their expenditure 
levels in pharmaceuticals, as well as hospitals’ total expenditure in these products. This 
feedback is available since August 2012 and physicians can check it by logging in their 
personal intranet page. However, some physicians may regularly control this 
information, while others may not even log in. Therefore, an interesting treatment, 
would be to do a survey to some physicians that, indirectly, would make them be aware 
of that feedback. Furthermore, in the specific case of HIV, it would be interesting to assess the impact of 
physicians prescribing pharmaceutical products together, by analysing the case of HSJ in comparison to the 
other five hospitals.  
Assuming two time periods, where treatment occurs only in period 2: 
Di1=0 – all  individuals in period 1 
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Di2=0 – untreated individuals in period 2 
Di2=1 – treated individuals in period 2 
∆yi = φ Di + δ + vi 
Where δ is a fixed effect and D i a binary treatment variable, indicating if the individual  
received, or not, treatment.  
The resulting estimator is called DD estimator because it estimates the time difference 




Thus, this method is going to be used to measure the causal effect of the treatment on 
















                                                          






C – Detailed Results 
C.1. – HIV 
C.1.1.Kolmogorov-Smirnov Test results 
Table 2 - Relative distribution results after the Kolmogorov-Smirnov test 
 
C.1.2. Comparisons among physicians – per hospital(s) where each one prescribes 
C.1.2.1. Overall period 
 
Alfredo da Costa; Capuchos; Curry e Cabral 
 
Estefânia; São José; Santa Marta 
 








 Semester of 2012 
 
Alfredo da Costa; Capuchos; Curry e Cabral 
 
Estefânia; São José; Santa Marta 
 
Capuchos and Curry e Cabral; Curry e Cabral and Capuchos; Curry e Cabral and Capuchos and S. José; Capuchos and S. José; 




S. José and Curry e Cabral; S. José and Capuchos; S. José and Santa Marta 
C.1.2.3. 2
nd
 Semester of 2012 
 
Capuchos; Curry e Cabral; Estefânia 
 
 
S. José; Santa Marta 
 




 Semester of 2013 
 




Estefânia; São José; Santa Marta 
 
Curry e Cabral and S. José; Curry e Cabral and Capuchos; Curry e Cabral and S. José and Capuchos; Capuchos and S. José 
 
Capuchos and S. José and Santa Marta; Estefânia and S. José; S. José and Santa Marta  
 
C.1.3. Comparisons among physicians – per medical specialty 
C.1.3.1 Overall period 
 
Anesthesiology; General Surgery; General and Family Practice; Dermatovenereology 
 




Infectiology; Occupational Medicine; General Medicine; Resident Physician 
 




 Semester of 2012  
 
 
General and Family Practice; Dermatovenereology; Gastroenterology; Gynecology & Obstetrics  
                
 
Clinical Hematology; Infectiology; Occupational Medicine; General Medicine 
 




 Semester of 2012  
 
Anesthesiology; General Surgery; Dermatovenereology; Gastroenterology  
 
 








 Semester of 2013 
 
General Surgery; General and Family Practice; Dermatovenereology; Gastroenterology   
 
Gynecology & Obstetrics; Infectiology; Occupational Medicine; General Medicine  
 
Resident Pysician; Nephrology; Clinical Pathology   
 
C.1.4. Expenditure levels across semesters 
C.1.4.1. Quantity and Unit Price 
 





2012 2nd-3rd Quarter 
 
2012 3rd- 4th Quarter 
 
2012 4th – 2013 1st Quarter  
 




C.2.5. Ordered probit results 
Table 3 – Ordered probit coefficients and p-values  
 
Table 4 - Probability of being an outlier with a below the norm expenditure level - P         
 
Table 5 - Probability of being an outlier with a below the norm expenditure level - P        
 
Table 6 - Probability of being an outlier with a below the norm expenditure level - P        
 
C.2. – Oncology 
C.2.1. Kolmogorov-Smirnov Test results 
Table 7 - Relative distribution results after the Kolmogorov-Smirnov test 
 
C.2.2. Comparisons among physicians – per hospital(s) where each one prescribes 
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C.2.2.1. Overall Period 
 
 
Alfredo da Costa; Capuchos; Curry e Cabral 
 





Alfredo da Costa and Estefânia; Curry e Cabral and Alfredo da Costa; Curry e Cabral and S. José; Capuchos and Alfredo da Costa 
 
Capuchos and S. José; S. José and Alfredo da Costa and Capuchos; S. José and Alfredo da Costa   
C.2.2.2. 1
st
 Semester of 2012 
 





Estefânia; S. José  
 
 
Alfredo da Costa and Capuchos; Alfredo da Costa and Capuchos and S. José; Alfredo da Costa and S. José; Capuchos and S. José  
 
S. José and Curry e Cabral  
C.2.2.3. 2
nd
 Semester of 2012 
 
Capuchos; Curry e Cabral; Estefânia; S. José 
 




S. José and Curry e Cabral  
C.2.2.4. 1
st
 Semester of 2013 
 
Alfredo da Costa; Capuchos; Curry Cabral 
 
S. José; Estefânia; Santa Marta  
 
Alfredo da Costa and Capuchos; Alfredo da Costa and Capuchos and S. José; Alfredo da Costa and Estefânia; Alfredo da Costa and 
S.José 
 
Curry e Cabral and S. José; Capuchos and S. José 
 
C.2.3. Comparisons among physicians – per medical specialty 
C.2.3.1 Overall period 
 




Gastroenterology; Gynecology & Obstetrics; Clinical Hematology; Infectiology  
 
 





 Semester of 2012 
 
Anesthesiology; General Surgery; Dermatovereology; Endocrineology  
 







 Semester of 2012 
 
Anesthesiology; General Surgery; Dermatovereology; Gynecology & Obstetrics 
 





 Semester of 2013 
 
Anesthesiology; General Surgery; Dermatovereology; Gastroenterology 
 




Medical Oncology; Pediatrics; Pneumology; Urology 
C.2.4. Expenditure levels across semesters 
C.2.4.1. Quantity and Unit Price 
 
2012 1st-2nd Quarter                                                  
 
2012 2nd-3rd Quarter 
 






2012 4th- 2013 1st Quarter 
 
2013 1st-2nd Quarter                                                  
  
C.2.5. Ordered probit results 
Table 8 – Ordered probit coefficients and p-values  
 




Table 10 - Probability of being an outlier with a below the norm expenditure level - P        
 
Table 11 - Probability of being an outlier with a below the norm expenditure level - P        
 
C.3. – Reumathism 
C.3.1. Kolmogorov-Smirnov Test results 
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Table 12 - Relative distribution results after the Kolmogorov-Smirnov test 
 
C.3.2. Comparisons among physicians – per hospital(s) where each one prescribes 
C.3.2.1. Overall Period 
 
 
Capuchos; Curry e Cabral; Estefânia 
 C.3.2.2. 1
st
 Semester of 2012 
 
 
Capuchos; Curry e Cabral; Estefânia 
C.3.2.2. 2
nd
 Semester of 2012 
 
Capuchos; Curry e Cabral; Estefânia 
C.3.2.3. 1
st




Capuchos; Curry e Cabral; Estefânia 
C.3.3. Comparisons among physicians – per medical specialty 
C.3.3.1. Overall period 
 
Anesthesiology; Dermatovereology; General Medicine; Pediatrics 
C.3.3.2. 1
st
 Semester of 2012 
 
Dermatovereology; General Medicine; Pediatrics  
C.3.3.3. 2
nd
 Semester of 2012 
 
Anesthesiology; Dermatovereology; General Medicine; Pediatrics  
C.3.3.4. 1
st




 Dermatovereology; General Medicine; Pediatrics  
C.3.4. Expenditure levels across semesters 
C.3.4.1. Quantity and Unit Price 
 
2012 1st-2nd Quarter                                                  
 




2012 3rd- 4th Quarter
 
2012 4th – 2013 1st Quarter 
 
2013 1st-2nd Quarter                                                  
 
D. Detailed diseases’ description 
D.1. HIV 
Pharmaceutical products for HIV/AIDS related diseases are fully paid by the Portuguese 
National Health System (PNHS) since 1996.2
 3
The PNHS takes the responsibility to 
offer healthcare in all the disease stages of a person that is HIV-positive. Indeed, it was 
in 1996 that an important treatment was introduced: the antiretroviral treatment. This 
treatment consists of combining at least three antiretroviral drugs, as a way to supress 
the virus and limit its progression.
4
 Therefore, this disease started to be considered as 
chronic, associated with a decrease in mortality and morbidity, allowing patients to be 
in the labour market.   
                                                          
2 Decree Law n.º 280/96 
3 Decree Law nº 25.360/01 
4 WHO (2010) 
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 Since the 1
st
 of December 2012, all hospitals belonging to the PNHS are required to use 
the SI.VIDA system.
5
 This system was created with the aim of monitoring the National 
Program for HIV/SIDA Infection. Its main objective is to register every activity related 
to the supply of HIV/AIDS related healthcare, which means that every prescription has 
to be done electronically. Prescriptions have to be done by physicians which are 
specialists in HIV, which can include physicians whose medical specialty is 
Infectiology or General Medicine.
6
   
D.2. Oncology 
The Directorate-General of Health is currently elaborating clinical guidelines for the 
different types of cancer as a way to improve medical practice.  
The payment for oncology treatments assumes a treatment that lasts 25 months and 
distinguishes three different types: breast cancer, uterine cancer and colorectal cancer. 
However, this payment procedure is still only applied to some hospitals, not including 
the ones belonging to the Centro Hospitalar de Lisboa Central. Therefore, it is assumed 
that different types of cancer require different a treatment so, costs are not comparable 
across the different pathologies.
7
  
Table 13 – Costs of cancer by type per patient/month 
 
  
                                                          
5 Decree Law nº 6716/2012 
6
 Decree Law n.º 280/96 
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